Myelofibrosis
Welcome,         Profile    Billing    Logout  
 150 Companies   90 Products   90 Products   70 Mechanisms of Action   203 Trials   12937 News 
252 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Myelofibrosis
ChiCTR-IIh-16008649: The value of dasatinib in the treatment of primary myelofibrosis

Recruiting
4
5
 
Dasatinib
The Peoples' Hospital of Jiaozuo City; The Peoples’ Hospital of Jiaozuo City, Beijing Medical Award Foundation
primary myelofibrosis
 
 
ChiCTR1900025219: A prospective, open-label, multicenter clinical trail for Ruxolitinib combined with Prednisone, Thalidomide and Danazole in adult patients wiht myelofibrosis

Not yet recruiting
4
80
 
Ruxolitinib combined with Prednisone, Thalidomide and Danazol
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
myelofibrosis
 
 
NCT05447260: A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Recruiting
4
87
RoW
Ruxolitinib
Qilu Hospital of Shandong University
Myelofibrosis
12/22
12/23
CINC424A2X01B, NCT02386800 / 2014-003527-22: Rollover Protocol

Active, not recruiting
4
279
Europe, Canada, Japan, RoW
ruxolitinib, INC424, Jakavi, panobinostat, LBH589, Farydak
Novartis Pharmaceuticals
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
09/27
09/27
ACTRN12614000740695: Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326)

Recruiting
3
300
 
Cell Therapeutics Inc., Cell Therapeutics Inc.
Primary Myelofibrosis
 
 
2011-001919-31: DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy, Toxicity and Quality of Life DALIAH Dansk Studie af Lav-dosis Interferon Alpha vs Hydroxyurea i Behandlingen af Ph-Negative kroniske myeloproliferative neoplasier “Et Nationalt Randomiseret Prospektivt Kvalitetssikringsstudie med Særlig Fokus på Effekt, Toxicitet og Livskvalitet”

Ongoing
3
200
Europe
Suspension for injection in pre-filled pen, Capsule, hard, Pegasys, PegIntron, Hydrea
Roskilde sygehus, Swedish Orphan, Ellen og Aage Fausbølls Helsefond af 1975, Fonden til lægevidenskabens Fremme, Odense Universitetshospitals forskningspulje, Region Sjællands og Region Syddanmarks fælles forskningspulje
Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-004239-21: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia)

Ongoing
3
75
Europe
pacritinib, SB1518,
CTI BioPharma Corp., CELL THERAPEUTICS INC., CTI BioPharma Corp., Cell Therapeutics Inc
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
 
 
2013-004000-19: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) in patients with a low platelet count

Ongoing
3
50
Europe
pacritinib, SB1518,
CTI BioPharma Corp., Cell Therapeutics, Inc., CTI BioPharma Corp., Cell Therapeutics, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia
 
 
2020-000111-69: PACIFICA Phase 3: A Study of Pacritinib Versus Physician’s Choice in Patients with Myelofibrosis

Ongoing
3
399
RoW, Europe
Pacritinib, Ruxolitinib, Hydroxyurea, methylprednisolone, Dexamethasone, Prednisone, [N/A], [Pacritinib], Capsule, hard, Tablet, Soluble tablet
CTI BioPharma Corp., Sobi Inc., CTI BIOPHARMA CORP., CTI BioPharma Corp., Sobi Inc.
Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis, Primary or Secondary Myelofibrosis (MF), Diseases [C] - Cardiovascular Diseases [C14]
 
 
2020-003415-98: A phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosis

Ongoing
3
212
Europe
parsaclisib, INCB050465, Tablet
Incyte Corporation, Incyte Corporation
myelofibrosis, myelofibrosis, Diseases [C] - Cancer [C04]
 
 
2020-003130-21: A phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosis

Ongoing
3
440
Europe
parsaclisib, INCB050465, Tablet
Incyte Corporation, Incyte Corporation
myelofibrosis, myelofibrosis, Diseases [C] - Cancer [C04]
 
 
2020-004652-15: AVAJAK: Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myelo-proliferative neoplasms AVAJAK: Apixaban/rivaroxaban Versus Aspirine en prévention primaire des complications thromboemboliques des néoplasies myéloprolifératives mutées pour JAK2V617F

Not yet recruiting
3
1340
Europe
Tablet, Gastro-resistant capsule, Eliquis, Xarelto, Aspirine Protec
CHRU de Brest, PHRC-K
Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis Néoplasies myéloprolifératives incluant les thrombocytémies essentielles, polyglobulies de Vaquez et pyélofibroses préfibrotiques, Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis Néoplasies myéloprolifératives incluant les thrombocytémies essentielles, polyglobulies de Vaquez et pyélofibroses préfibrotiques, Diseases [C] - Cancer [C04]
 
 
FREEDOM, NCT03755518: A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Completed
3
38
Canada, US
FEDRATINIB
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
11/21
11/23
MOMENTUM, NCT04173494 / 2019-000583-18: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants

Calendar Jan 2024 - Dec 2024: Regulatory approval in EU (based on MOMENTUM trial) for myelofibrosis
Hourglass Jan 2023 - Jun 2023 : Approval in US for myelofibrosis (based on MOMENTUM trial)
Jun 2023 - Jun 2023: Anticipated FDA action date for NDA in myelofibrosis based on MOMENTUM trial
Checkmark New data from MOMENTUM trial in myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: New data from MOMENTUM trial in myelofibrosis at ASH 2022
More
Completed
3
195
Europe, Canada, US, RoW
Momelotinib, MMB, GS-0387, CYT387, Placebo to match danazol, Danazol, Danocrine, Placebo to match momelotinib
Sierra Oncology LLC - a GSK company
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
12/21
12/22
FREEDOM2, NCT03952039 / 2018-003411-21: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Active, not recruiting
3
202
Europe, RoW
FEDRATINIB, Best Available Therapy (BAT)
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
12/22
06/25
NCT03480360: Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Active, not recruiting
3
21
US
Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant
Dartmouth-Hitchcock Medical Center
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
03/23
09/25
TRANSFORM-1, NCT04472598 / 2020-000097-15: Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Calendar Jan 2024 - Dec 2024: Approval for 1L myelofibrosis (based on TRANSFORM-1 trial)
Jan 2023 - Dec 2023: Data readout from TRANSFORM-1 trial in combination with Jakafi oral for myelofibrosis
Active, not recruiting
3
252
Europe, Canada, Japan, US, RoW
Navitoclax, ABT-263, Ruxolitinib, Placebo for Navitoclax
AbbVie
Myelofibrosis (MF)
04/23
01/25
ChiCTR2100046946: A Phase III, Randomized, Double-Blind Controlled Trial for Evaluating Jaktinib vs. Hydroxycarbamide in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Recruiting
3
105
 
Jaktinib hydrochloride tablets，100mg bid ;Hydroxycarbamide tablets 0.5g bid
The First Affiliated Hospital of Medical School of Zhejiang University; Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post- essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
 
 
LIMBER-313, NCT04551066: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Active, not recruiting
3
252
Europe, Japan, US, RoW
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
08/23
11/24
LIMBER-304, NCT04551053: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Oct 2023 - Dec 2023: Data from LIMBER-304 trial n combination with ruxolitinib for myelofibrosis
Terminated
3
177
Europe, Japan, US, RoW
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
08/23
08/24
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT04816578: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Recruiting
3
440
US
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
09/23
02/26
NCT04816565: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Not yet recruiting
3
212
Europe, US
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
11/23
12/23
ZGJAK016, NCT04617028: Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Completed
3
105
RoW
Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets, Placebo to match Jaktinib
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Myelofibrosis
10/23
10/23
ChiCTR2100047040: A Phase iii Study for Evaluating Jaktinib vs Hydroxycarbamide in Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Recruiting
3
105
 
Jaktinib, 100mg, bid ;Hydroxycarbamide, 0.5g，bid
The First Affiliated Hospital of Medical School of Zhejiang University; West China Hospital of Sichuan University, Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post- essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
 
 
MK-3543-017, NCT06351631: A Study to Evaluate Safety and Efficacy of Bomedemstat

Recruiting
3
400
Europe, US, RoW
Bomedemstat, MK-3543, IMG-7289
Merck Sharp & Dohme LLC
Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
12/34
12/34
POIESIS, NCT06479135: Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Recruiting
3
600
Europe, US, RoW
Navtemadlin, KRT-232, Navtemadlin placebo, Ruxolitinib, Jakafi, Jakavi
Kartos Therapeutics, Inc.
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
12/26
12/28
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Calendar Jan 2024 - Dec 2024: Submission for r/r myelofibrosis in combination with Jakafi (based on TRANSFORM-2 trial)
Calendar Jan 2024 - Dec 2024: Data readout from TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Active, not recruiting
3
295
Europe, Canada, Japan, US, RoW
Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
01/25
01/25
NCT06468033: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Not yet recruiting
3
150
NA
Ropeginterferon alfa-2b, P1101, Placebo
PharmaEssentia
Primary Myelofibrosis, Myeloproliferative Neoplasm
03/27
04/28
INDEPENDENCE, NCT04717414 / 2020-000607-36: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Calendar Jan 2025 - Dec 2025: Data from INDEPENDENCE trial for myelofibrosis
Checkmark From INDEPENDENCE trial for myelofibrosis associated anemia
Jun 2021 - Jun 2021: From INDEPENDENCE trial for myelofibrosis associated anemia
Active, not recruiting
3
309
Europe, Canada, Japan, US, RoW
ACE-536, Luspatercept, BMS-986346, Placebo
Celgene, Celgene Corporation
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
03/25
08/25
PACIFICA, NCT03165734 / 2017-001772-28: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Calendar May 2026 - Sep 2026: Data from PACIFICA trial for myelofibrosis
Recruiting
3
399
Europe, Canada, US, RoW
Pacritinib, Physician's Choice medications, corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib
Swedish Orphan Biovitrum, Sobi, Inc., PSI CRO
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
06/25
12/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
More
Recruiting
3
330
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
IMpactMF, NCT04576156 / 2020-003288-24: A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Calendar Jan 2025 - Dec 2025: Final analysis data from IMpactMF trial for refractory myelofibrosis
Calendar Jan 2024 - Dec 2024: Interim analysis data from IMpactMF trial for refractory myelofibrosis
Checkmark Trial updates from IMpactMF trial for relapsed/refractory myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Trial updates from IMpactMF trial for relapsed/refractory myelofibrosis at ASH 2022
Recruiting
3
320
Europe, US, RoW
Imetelstat, GRN163L, Best Available Therapy (BAT)
Geron Corporation
Myelofibrosis
11/26
11/26
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting
3
1308
Europe
Direct Oral Anticoagulants, Low-dose aspirin
University Hospital, Brest
Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients
07/27
07/27
LTFU, NCT04064060 / 2018-002915-93: A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Recruiting
3
665
Europe, Canada, Japan, US, RoW
Luspatercept, ACE-536
Celgene
Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
05/28
05/28
BOREAS, NCT03662126 / 2018-001671-21: KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Recruiting
2/3
385
Europe, Canada, US, RoW
KRT-232, Best Available Therapy (BAT)
Kartos Therapeutics, Inc., Kartos Therapeutics, Inc.
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
12/23
12/25
NCT00095784: Decitabine in Treating Patients With Myelofibrosis

Active, not recruiting
2
21
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Primary Myelofibrosis, Secondary Myelofibrosis
07/08
02/25
2009-014980-38: Bone marrow transplantation from a donor to a patient who have incompatible blood cells. Before transplantation, patients will receive a less intensive treatment with a low-dose chemiotherapy. The day of transplantation, patients will be injected with a population of blood cells from the donor as well as a specific cell population, named mesenchymal stem cells.

Ongoing
2
120
Europe
mesenchymal stem cells, MSC
CHU de Liège
Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in blast crisis; - Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis; - MDS with < 5% blasts; - Multiple myeloma not rapidly progressing; - CLL; - Non-Hodgkin’s lymphoma (aggressive NHL should have chemosensitive disease); - Hodgkin’s disease, Types of cancer that affect blood, bone marrow and lymph nodes., Diseases [C] - Cancer [C04]
 
 
NCT00398346: Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Recruiting
2
68
US
therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Secondary Myelofibrosis, Small Intestine Cancer
12/10
 
NCT01242709: Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Not yet recruiting
2
54
US
AB0024
Arresto Biosciences, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
12/11
12/13
NCT01534767: Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Recruiting
2
19
US
sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia
06/13
10/13
NCT01414127: Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT

Active, not recruiting
2
22
US
tacrolimus, FK 506, Prograf, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell
Barbara Ann Karmanos Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
10/13
10/13
2012-005010-19: Exploring the potential of adding the drug Ruxolitinib to the standard reduced intensity (lower strength) chemotherapy regimen prior to bone marrow transplant in patients with myelofibrosis.

Ongoing
2
86
Europe
Ruxolitinib (INC424), Tablet, Jakavi
Consorzio Mario Negri Sud, National Cancer Institute, Leukaemia & Lymphoma Research
Primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF), MF is a form of bone marrow cancer in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring., Diseases [C] - Cancer [C04]
 
 
2007-001413-42: Study of Fludarabine based conditioning for Allogeneic Stem cell Transplantation for Myelofibrosis

Ongoing
2
20
Europe
FLUDARA, ALKERAN*1FL 50MG/10ML+FL 10ML, THYMOGLOBULINE*1F 25MG+1F 5ML, FLUDARA, ALKERAN*1FL 50MG/10ML+FL 10ML, THYMOGLOBULINE*1F 25MG+1F 5ML
AZIENDA OSPEDALIERA \"OSPEDALI RIUNITI DI BERGAMO\" (A.O. DI RILIEVO NAZIONALE)
MYELOFIBROSIS
 
 
2011-005414-10: Nordic Study of Multiferon® in Early-Stage Primary Myelofibrosis - a Multicentre Pilot Study

Ongoing
2
20
Europe
Multiferon, Multiferon
The Nordic Myeloproliferative Neoplasm Group, Swedish Orphan Biovitrum
early and fibrotic stages of primary myelofibrosis
 
 
2013-003295-12: Kombinationsbehandling med Interferon og JAK1-2 Hæmmer i behandlingen af Ph-Negativ Myeloprolifertiv Cancer

Ongoing
2
50
Europe
Jakavi, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram
Roskilde University Hospital, Novartis
Polycythemia vera Hyperproliferativ myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2014-001367-13: The study to assess the efficacy and safety of new Interferon alpha-2b formulation in patients with primary myelofibrosis

Ongoing
2
24
Europe
Pegylated proline-interferon alpha- 2b, AOP2014,
Medizinische Universtät Wien, Universitätsklinik für Innere Medizin I, AOP ORPHAN PHARMACEUTICALS AG
Primary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteria
 
 
2014-005210-28: Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial Ruxolitinib Behandlung versus allogene Stammzelltransplantation bei Patienten mit Myelofibrose in Abhängigkeit von der Spenderverfügbarkeit

Ongoing
2
155
Europe
allogeneic HSC, allogeneic HSC, Solution for infusion, Tablet, Jakavi
University Medical Center Hamburg-Eppendorf, University Medical Center Hamburg-Eppendorf
primary myelofibrosis primäre Myelofibrose, progressive bone marrow disease (bone marrow cancer) fortschreitende Erkranung des Knochenmarks (Knochenmarkkrebs), Diseases [C] - Cancer [C04]
 
 
2016-001406-42: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.

Ongoing
2
100
Europe
Atorvastatin, Zoledronic acid, Tablet, Concentrate for solution for injection/infusion
Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde, Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde
The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis., Chronic bloodcancer, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02506933: Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Active, not recruiting
2
102
US
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Placebo, placebo therapy, PLCB, sham therapy
City of Hope Medical Center, National Cancer Institute (NCI), Diavax Biosciences
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hodgkin Lymphoma, Lymphadenopathy, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
01/18
12/24
NCT02396134: Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, not recruiting
2
61
US
CMVpp65-A*0201 peptide vaccine, Placebo, placebo, Placebo, placebo therapy, PLCB, sham therapy, Laboratory Biomarker Analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
03/18
12/24
ChiCTR1900022306: Jakotinib hydrochloride tablets in the treatment of safety and efficacy in patients with high-risk myelofibrosis multicenter Ⅱ phase of clinical trials

Not yet recruiting
2
100
 
Jakotinib hydrochloride tablets, 100mg/bid ;Jakotinib hydrochloride tablets, 200mg/qd
The First Affiliated Hospital, Zhejiang University; Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Zelgen), Provided by the sponsor
PMF、Post-PV-MF、Post-ET-MF
 
 
2020-003087-45: Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral GB2064 in participants with myelofibrosis. Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Pharmakodynamik von oralem GB2064 bei Teilnehmern mit Myelofibrose.

Not yet recruiting
2
24
Europe
GB2064, PAT-1251, Tablet
Galecto Biotech AB, Galecto Biotech AB
Primary (PMF) or secondary (SMF) myelofibrosis., Primary (PMF) or secondary (SMF) myelofibrosis., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-005642-42: Clinical Trial of 2 separate investigational products (KRT-232 and TL-895) to assess their safety and effectiveness in treating patients with Myelofibrosis.

Not yet recruiting
2
104
Europe, RoW
KRT-232, TL-895, KRT-232, TL-895, Tablet, Film-coated tablet
Kartos Therapeutics, Inc., Kartos Therapeutics, Inc.
Primary, post-polycythemia vera (PV), or post-essential thrombocythemia (ET) myelofibrosis (MF), who are treatment naïve to any JAK inhibitor., Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
2017-005109-11: A study evaluating the impact of Itacitinib alone or when added to ruxolitinib for the treatment of myelofibrosis

Not yet recruiting
2
42
Europe
Itacitinib, INCB039110, Modified-release tablet
Incyte Corporation, Incyte Corporation
Myelofibrosis, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
2021-002042-32: A phase II study of CPX-351 monotherapy in Acute Myeloid Leukemia secondary to Myeloproliferative neoplams Étude de phase II d’une monothérapie par cpx-351 dans les leucémies aiguës secondaires à un syndrome myéloprolifératif

Not yet recruiting
2
42
Europe
Vyxeos, CPX-351, Powder for concentrate for solution for injection/infusion, CPX-351, VYXEOS
FILO, FILO, JAZZ PHARMACEUTICAL
newly secondary AML according to WHO 2016 classification following an antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET), Polycythemia Vera (PV), primary or secondary Myelofibrosis Premier diagnostic de LAM secondaires selon la classification OMS 2016 avec un antécédent de néoplasie myeloproliferative (NMP) incluant une thrombocytémie essentielle (TE), une polyglobulie primitive (PV), une myélofibrose primitive ou secondaire, newly secondary AML following an antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET), Polycythemia Vera (PV), primary or secondary Myelofibrosis Premier diagnostic de LAM secondaires selon la classification OMS 2016 avec un antécédent de néoplasie myeloproliferative (NMP) incluant une TE, une PV, ou une myélofibrose primitive ou secondaire, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-003227-15: KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis KER-050 come monoterapia o in combinazione con Ruxolitinib in partecipanti con mielofibrosi

Not yet recruiting
2
110
Europe
KER-050, Jakavi, [PRD8997233], [Ruxolitinib], [ruxolitinib], Solution for injection/infusion, Tablet, Jakavi
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Myelfibrosis (MF)MF- associated cytopenias Myelfibrosis (MF)MF- associated cytopenias, MF is a chronic myeloproliferative malignancy characterized by clonal proliferation of myeloid cells and megakaryocytic hyperplasia/dysplasia resulting in bone marrow fibrosis and osteosclerosis. MF is a chronic myeloproliferative malignancy characterized by clonal proliferation of myeloid cells and megakaryocytic hyperplasia/dysplasia resulting in bone marrow fibrosis and osteosclerosis., Diseases [C] - Cancer [C04]
 
 
REFINE, NCT03222609 / 2017-001398-17: A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Checkmark Data from P2 REFINE trial for myelofibrosis
Dec 2022 - Dec 2022: Data from P2 REFINE trial for myelofibrosis
Checkmark Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from P2 REFINE trial in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis at ASH 2022
Active, not recruiting
2
191
Europe, Canada, Japan, US, RoW
Ruxolitinib, Jakafi, Navitoclax, ABT-263
AbbVie
Myelofibrosis (MF)
03/22
01/25
NCT04543279: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Terminated
2
3
US
Fostamatinib, Tavalisse, Ruxolitinib, Jakafi
Washington University School of Medicine, Rigel Pharmaceuticals
Myelofibrosis, Thrombocytopenia
07/22
07/22
2018-003811-23: A study to test the safety and effects of IMG-7289 in patients with myelofibrosis.

Not yet recruiting
2
75
Europe, RoW
IMG-7289, IMG-7289, Capsule, hard
Imago BioSciences, Inc., Imago BioSciences Inc., Imago BioSciences, Inc, Imago BioSciences, Inc.
Patients with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera myelofibrosis (PPV-MF), and post-essential thrombocythaemia myelofibrosis (PET-MF) (collectively referred to as ‘MF’), Myelofibrosis: a condition in which the bone marrow is gradually replaced by fibrous, scar-like tissue that prevents the marrow from making normal blood cells., Diseases [C] - Cancer [C04]
 
 
2021-003650-23: Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Studie zur Beurteilung der Wirksamkeit und Sicherheit von Fedratinib in Kombination mit CC-486 bei Patient*innen, die an einer Myelofibrose in beschleunigter Phase leiden.

Not yet recruiting
2
44
Europe
CC-486 tablets, Capsule, hard, Film-coated tablet, Inrebic® 100 mg Hartkapseln
Martin-Luther-Universität Halle-Wittenberg, Bristol-Myers Squibb
Myeloproliferative neoplasm in accelerated phase (MPN-AP) Myeloproliferative Neoplasie in akzelerierter Phase (MPN-AP), Myeloproliferative neoplasm in accelerated phase (MPN-AP) Myeloproliferative Neoplasie in beschleunigter Phase (MPN-AP), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ZGJAK006, NCT04217993: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Completed
2
51
RoW
Jaktinib hydrochloride tablets, Jaktinib
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
08/22
08/22
NCT03333486: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Active, not recruiting
2
31
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation
Roswell Park Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
08/23
08/24
NCT04851535: Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Completed
2
34
RoW
Jaktinib Hydrochloride Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Myelofibrosis
11/22
11/22
2022-003009-31: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis Atorvastatin til patienter med de Philadelphia-negative kronisk myeloproliferative neoplasier - essentiel trombocytose, polycythemia vera og prefibrotisk myelofibrose

Not yet recruiting
2
40
Europe
Atorvastatin, Coated tablet
Zealand University Hospital, dept. of Haematology, Region Zealand
Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis, blood cancer, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
P30CA015704, NCT02251821: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Active, not recruiting
2
61
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, allogeneic stem cell transplantation, HSC, HSCT, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Mycophenolate Mofetil, Cellcept, MMF, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, Jakafi, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation, SCT_TBI, Umbilical Cord Blood Transplantation, Cord Blood Transplantation, UCB transplantation
Fred Hutchinson Cancer Center, Incyte Corporation, National Cancer Institute (NCI)
Primary Myelofibrosis, Secondary Myelofibrosis
12/22
12/25
LIMBER-213, NCT04821791: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy.

Recruiting
2
60
US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
02/23
02/23
NCT02722668: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Active, not recruiting
2
16
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, MMF, Mycophenolate Mofetil, Sirolimus, Rapamycin, TBI, Total body irradiation, Umbilical cord blood cell infusion, UCB, ATG, Anti-thymocyte Globulin
Masonic Cancer Center, University of Minnesota
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-cell Lymphoma, Prolymphocytic Leukemia, Bone Marrow Failure Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Leukemia or MDS in Aplasia, Relapsed T-Cell Lymphoma, Relapsed Multiple Myeloma, Plasma Cell Leukemia
02/23
12/29
TQ05105-â…¡-01, NCT05020652: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Recruiting
2
105
RoW
TQ05105 tablets, Hydroxycarbamide tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Moderate and High Risk Myelofibrosis
03/23
09/23
2021-000369-34: A Phase 2b, Open-label, Multicenter,Randomized, Controlled,2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 versus Best Available Therapy in Subjects with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/μL)

Not yet recruiting
2
120
Europe
NS-018, NS-018, Tablet
NS Pharma, Inc., NS Pharma, Inc, NS Pharma, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosiswith Severe Thrombocytopenia, Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
Study 0314, NCT02268253: Tagraxofusp (SL-401) in Patients With CMML or MF

Hourglass Jan 2021 - Mar 2021 : Data from trial for CMML and myelofibrosis
Checkmark Initiation of stage 3 pivotal program of P1/2 trial for CMML
Dec 2019 - Dec 2019: Initiation of stage 3 pivotal program of P1/2 trial for CMML
Checkmark From trial in relapsed/refractory myelofibrosis at ASH 2019
Dec 2019 - Dec 2019: From trial in relapsed/refractory myelofibrosis at ASH 2019
More
Completed
2
82
Canada, US
SL-401, tagraxofusp-erzs
Stemline Therapeutics, Inc.
Myelofibrosis, Chronic Myelomonocytic Leukemia
03/23
03/23
NCT04339101: Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Active, not recruiting
2
59
US
Fludarabine, Fluradosa, Itacitinib Adipate, INCB-039110 Adipate, INCB039110 Adipate, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sirolimus, AY 22989, RAPA, Rapamune, rapamycin, SILA 9268A, WY-090217, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
05/23
12/24
NCT03289910: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Active, not recruiting
2
25
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Topotecan, Hycamptamine, Topotecan Lactone, Topotecan Hydrochloride, Evotopin, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/23
12/24
HOVON134MF, NCT03645824 / 2015-000195-98: Myelofibrosis Treated With Pacritinib Before aSCT.

Active, not recruiting
2
61
Europe
Pacritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland, Dutch Cancer Society, CTI BioPharma
Myelofibrosis
07/23
02/27
2020-003123-42: A study evaluating safety, tolerability and efficacy of Itacitinib in participants with primary or secondary Myelofibrosis

Not yet recruiting
2
73
Europe
Itacitinib, INCB039110, Tablet
Incyte Corporation, INCYTE CORPORATION, Incyte Corporation
Primary Myelofibrosis or Secondary Myelofibrosis, Primary Myelofibrosis or Secondary Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
NCT04629508: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Completed
2
4
Europe, US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
08/23
08/23
NCT04655118 / 2020-002393-27: Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Recruiting
2
121
Europe, US, RoW
TL-895, Placebo
Telios Pharma, Inc.
Myelofibrosis, Indolent Systemic Mastocytosis
06/25
12/25
NCT04644016: Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Recruiting
2
31
US
Clofarabine, Clolar, Fludarabine, Fludara, Busulfan, Busulfex, Cyclosporine-A, CSA, Mycophenolate Mofetil, MMF, Cord Blood Graft, CB graft
Memorial Sloan Kettering Cancer Center
AML, ALL, MDS, MPD Withou Myelofibrosis, NHL or HL, Inherited Metabolic Disorders, Hemoglobinopathies, Bone Marrow Failure, HLH
12/25
12/25
NCT00719888: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Active, not recruiting
2
135
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cyclosporine, 27-400, Ciclosporin, CsA, Cyclosporin, Cyclosporin A, Gengraf, Neoral, OL 27-400, Sandimmun, Sandimmune, SangCya, Double-Unit Umbilical Cord Blood Transplantation, Fludarabine, 118218, Fluorovidarabine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Cellcept, MMF, Total-Body Irradiation, Total Body Irradiation, Whole-Body Irradiation, SCT_TBI, TBI, Umbilical Cord Blood Transplantation, Cord Blood Transplantation, UCB transplantation, Thiotepa, 1,1',1"-phosphinothioylidynetrisaziridine, 1,1',1''-Phosphinothioyldynetrisaziridine, 52-24-4, 6396, Girostan, Triethylenethiophosphoramide, Triethylene Thiophosphoramide
Fred Hutchinson Cancer Center
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
12/23
12/24
AIRPORT-MPN, NCT04243122: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Completed
2
44
Canada
Apixaban 2.5 MG Oral Tablet [ELIQUIS], Eliquis, Aspirin 81 mg, Acetylsalicylic acid
Ottawa Hospital Research Institute, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, the Association médicale universitaire de l'Hôpital Montfort (AMUHM), Canadian Hematology Society
Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET), JAK2 Mutation, Polycythemia Vera (PV), Primary Myelofibrosis, Venous Thromboembolism (VTE)
10/23
05/24
MYLOX-1, NCT04679870: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
FIBRAPLO, NCT04728490: Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study

Not yet recruiting
2
28
NA
Allogenic transplantation transplantation
Assistance Publique - Hôpitaux de Paris
Myelofibrosis
01/24
01/24
NCT03069326: A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

Active, not recruiting
2
30
US
Ruxolitinib, Thalidomide
Memorial Sloan Kettering Cancer Center, Incyte Corporation, Celgene, M.D. Anderson Cancer Center
Myelofibrosis
02/25
02/25
NCT04218071: Actuate 1901: 9-ING-41 in Myelofibrosis

Completed
2
17
US
Ruxolitinib, Jakafi, 9-ING-41, 9-ING-41 Compound
Actuate Therapeutics Inc.
Myelofibrosis
10/22
01/24
ESSENTIAL, NCT03627403: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Checkmark Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Nov 2022 - Nov 2022: Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Checkmark Data from ESSENTIAL trial for myelofibrosis
Nov 2021 - Nov 2021: Data from ESSENTIAL trial for myelofibrosis
Checkmark New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
More
Active, not recruiting
2
17
US
Selinexor
University of Utah, Karyopharm Therapeutics Inc
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
08/23
03/25
NCT04854096: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Terminated
2
7
Europe, US, RoW
NS-018, Best Available Therapy
NS Pharma, Inc., Nippon Shinyaku Co., Ltd.
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
05/24
05/24
MPN-RC 119, NCT04281498: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Completed
2
6
Canada, US
Ruxolitinib, Enasidenib
John Mascarenhas, Celgene Corporation, Incyte Corporation, Myeloproliferative Neoplasms Research Consortium, National Institutes of Health (NIH), National Cancer Institute (NCI)
Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
05/23
05/23
NCI-2022-03765, NCT05364762: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

Recruiting
2
50
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Itacitinib, INCB 039110, INCB-039110, INCB039110, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Quality-of-Life Assessment, Quality of Life Assessment, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
05/26
05/26
NCT03427866: Ruxolitinib Pre-, During- and Post-HSCT for Patients with Primary or Secondary Myelofibrosis.

Active, not recruiting
2
44
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Myelofibrosis
05/24
05/25
NCT04878003: Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Recruiting
2
52
Europe, US, RoW
KRT-232, TL-895
Kartos Therapeutics, Inc.
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
05/24
10/25
NCT06457425: Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial

Recruiting
2
75
RoW
Flonoltinib 50mg, Flonoltinib 100mg, Ruxolitinib
Chengdu Zenitar Biomedical Technology Co., Ltd
MF,PMF,PPV-MF,PET-MF
05/26
07/26
NCT05467800: Study of Canakinumab in Patients With Myelofibrosis

Recruiting
2
10
US
Canakinumab
John Mascarenhas
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
01/25
07/26
NCT02370329: P1101 in Treating Patients with Myelofibrosis

Completed
2
11
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Ropeginterferon Alfa-2B, AOP2014, Besremi, P-1101, P1101, PEG-P-IFN-Alfa-2b, PEG-P-IFN-Alpha-2b, PEG-Proline-Interferon Alfa-2b
Mayo Clinic, National Cancer Institute (NCI)
Primary Myelofibrosis, Secondary Myelofibrosis
11/23
11/23
TREATMORE, NCT06541249: MethoTRExATE in MyelOpRolifErative Neoplasms () Trial

Not yet recruiting
2
54
US
Methotrexate (MTX)
Icahn School of Medicine at Mount Sinai
Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)
07/27
07/28
NCT06327100: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Recruiting
2
33
US
Ruxolitinib, Jakafi, INCB018424, INC424, Tasquinimod
M.D. Anderson Cancer Center, Active Biotech AB
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
05/29
05/31
NCI-2017-00614, NCT02861417: Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Active, not recruiting
2
204
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Cellcept, MMF, Pharmacological Study, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Thiotepa, 1,1'',1''''-Phosphinothioylidynetrisaziridine, Girostan, N,N'', N''''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
08/25
08/25
NCT04370301: Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting
2
20
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, WR-138719, JAK Inhibitor, JAK inhibitors, Janus Kinase Inhibitor, Ruxolitinib, Fedratinib, Fludarabine, Fluradosa, Recombinant Granulocyte Colony-Stimulating Factor, Recombinant Colony-Stimulating Factor 3, rhG-CSF, 143011-72-7, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Mycophenolate Mofetil, Cellcept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, FK-506, Tacforius, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation, Total-Body Irradiation Prior to Stem Cell Transplant, SCT_TBI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Magnetic Resonance Imaging, MR Imaging, MRI, Bone Marrow Biopsy, Biopsy of Bone Marrow, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
Fred Hutchinson Cancer Center
Primary Myelofibrosis, Secondary Myelofibrosis
08/26
08/29
ChiCTR2200064250: Efficacy and Safety of Ruxoltinib in Patients with Lower Risk Myelofibrosis---a Single Arm, Exploratory and Prospective Study

Not yet recruiting
2
30
 
ruxoltinib
The Forth Affiliated Hospital Zhejiang University School of Medicine; The Forth Affiliated Hospital Zhejiang University School of Medicine, scientific research funds
Myelofibrosis
 
 
POTAMI-61, NCT06397313: RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
NCT02784496: Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

Completed
2
8
US
Long-term Follow-up, Quality-of-Life Assessment, Quality of Life Assessment, Ruxolitinib, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Myelofibrosis
01/24
01/24
 

Download Options